Modality
Peptide
MOA
CGRPant
Target
TNFα
Pathway
Tau
GBMCTCLNarcolepsy
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
~Oct 2022
→ ~Jan 2024
Phase 2
Apr 2024
→ Dec 2028
Phase 2Current
NCT04823620
2,485 pts·GBM
2024-04→2028-12·Active
2,485 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-252.7y awayPh2 Data· GBM
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2028-12-25 · 2.7y away
GBM
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04823620 | Phase 2 | GBM | Active | 2485 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |